European Medicines Agency confirms positive benefit-risk balance of Protelos / Osseor, but recommends new contraindications and revised warnings

View source ↗

Summary

The EMA confirms a positive overall benefit-risk for Protelos/Osseor but recommends new contraindications and revised warnings.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fracture Prevention
• Osteopenia
• Osteoporosis

Drugs mentioned

• Osseor (strontium ranelate)
• Protelos (strontium ranelate)